Navigation Links
RoosterBio Partners with Senti Biosciences to Rapidly Translate Gene Circuit Cell Therapy into the Clinic
Date:3/19/2020

RoosterBio Inc. announces a clinical supply and manufacturing collaboration agreement with pioneering gene circuit company Senti Biosciences, Inc. (Senti) to accelerate the clinical translation of Senti’s gene-modified cell therapies for ovarian cancer and other solid tumor indications. The collaboration will leverage RoosterBio’s human mesenchymal stem/stromal cell (hMSC) bioprocess systems, rapid product and process development platform, and current Good Manufacturing Practices (cGMP)-compliant, hMSC-focused manufacturing capabilities.

“Gene-modified cell therapies are one of the most important segments in our industry, and we are excited to help Senti Biosciences accelerate its technology into the clinic,” said RoosterBio’s Founder & Chief Product Officer Jon A. Rowley, PhD. “Our collaboration reflects the importance of strategically positioned gene engineering platforms that are designed for rapid clinical translation. RoosterBio’s goal of radically simplifying hMSC product development, process development and clinical manufacturing are being leveraged to move the field of cell therapy forward.”

“Gene circuits have the potential to lead the next wave of cell and gene therapies to address the high unmet need in difficult-to-treat cancers, such as ovarian cancer” said Philip Lee, PhD, Senti’s Chief Operating Officer and Co-Founder. “We look forward to continuing our collaboration with RoosterBio to accelerate clinical development of our novel gene circuit MSC-based therapies to help bring those therapies to patients as efficiently and safely as possible.”

Under the terms of the agreement, Senti will apply its novel gene circuit technology to hMSCs produced by RoosterBio’s breakthrough CliniControl™ hMSC manufacturing platform. In addition, Senti will employ RoosterBio for external development of hMSC supply and expansion, including bioreactor scale-up and industrialized large-scale manufacturing unit operations.

RoosterBio’s proprietary, clinically relevant product portfolio was introduced in 2017 under the CliniControl brand name with the promise to radically simplify multiple steps in therapeutic development. CliniControl is the first hMSC product to be commercialized as off-the-shelf, cGMP-compliant working cell bank and bioprocess media systems.

Rowley added, “We’ve shown that our CliniControl products can uniquely deliver and continue to drive unparalleled efficiencies and economies of scale in clinical and commercial hMSC manufacturing, helping our customers accelerate the development of exciting new cell therapy products.”

About RoosterBio, Inc.

RoosterBio, Inc. is a privately held cell manufacturing platform technology company focused on accelerating the development of a sustainable Regenerative Medicine industry, one customer at a time. RoosterBio's products are high-volume, affordable, and well-characterized adult human mesenchymal stem/stromal cells (hMSCs) paired with highly engineered media systems. RoosterBio has simplified and standardized how living cells are purchased, expanded, and used in development, leading to marked time and costs savings for customers. RoosterBio's innovative products are ushering in a new era of productivity and standardization into the field. Visit http://www.roosterbio.com.

About Senti Biosciences

Senti Biosciences is a next-generation therapeutics company that is developing gene circuits and programming cells for tremendous therapeutic value. Senti’s mission is to outsmart complex diseases with more intelligent medicines that will transform people’s lives. By programming cells to respond, adapt and make decisions, Senti is creating smarter therapies with computer-like logic, enhanced functionality and greater therapeutic control.

Senti’s product candidates address major challenges in cancer treatment. To overcome cancer immune evasion, Senti is building cell therapies equipped with combinatorial arming gene circuits to elicit broad and sustained anti-tumor immune responses. Senti is also developing next-generation cell therapies that more precisely target and eliminate cancer cells while sparing healthy tissue.

Senti Biosciences is based in South San Francisco and was founded in 2016 by Drs. Tim Lu, Philip Lee, Jim Collins and Wilson Wong. Senti is proud to count NEA, 8VC, Amgen Ventures, Lux Capital, Menlo Ventures, Pear Ventures, Allen & Company, Nest.Bio, Omega Funds, Goodman Capital, and LifeForce Capital among its investors.

Read the full story at https://www.prweb.com/releases/roosterbio_partners_with_senti_biosciences_to_rapidly_translate_gene_circuit_cell_therapy_into_the_clinic/prweb16984365.htm.


'/>"/>
Source: PRWeb
Copyright©2020 Vocus, Inc.
All rights reserved


Related biology technology :

1. RoosterBio and GenCure Sign Multiple Agreements to Advance Regenerative Medicine Startups
2. RoosterBio Launches New cGMP Stem Cell Product Portfolio, Maintaining Unwavering Commitment to Driving the Explosive Regenerative Medicine Industry
3. Margot Connor, CEO, RoosterBio Inc., Frederick Innovative Technology Center, Inc expected graduate earns “Top 10” Technology Industry Award
4. RoosterBio Launches a Xeno-Free Bioreactor Feed to Streamline Cell Expansion & Efficiently Reach Billions of hMSCs
5. RoosterBio Inc. Unites with Manufacturing Innovation Institutes, Joining Manufacturing USA Network
6. Engineered by RoosterBio Inc.: Universal Bioprocess Bags to Streamline Closed System Stem Cell Production
7. Designed by RoosterBio Inc.: New Xeno-free Cell Culture Media Product Developed to Accelerate Manufacturing and Commercialization of Adult Stem Cell Products
8. RoosterBio Inc. Launches Industry’s First Ready-to-Print Stem Cell Product
9. Sistemic and RoosterBio Inc Announce Broad Collaboration Agreement to Advance miRNA and Mesenchymal Stem/Stromal Cell (MSC) Regenerative Technology
10. Shoreline Biome Announces New Asian Distribution Partnership
11. With the Industry Booming, Slone Partners Celebrates 20 Years as a Leader in Life Sciences and Biotech Executive Search
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/10/2020)... N.J. (PRWEB) , ... March 10, 2020 , ... Ortho ... lives through innovative laboratory solutions, announced its ORTHOTM Sera, ID-MTS, a suite of extended ... of transfusion, is cleared to run on ORTHO VISION® and ORTHO VISION® Max in ...
(Date:3/10/2020)... ... March 10, 2020 , ... Lifecycle Biotechnologies announced ... in Cleburne, Texas to be used as a biopharmaceutical and biotechnology production and development ... sales offices as well as its production and development hub. The company expects to ...
(Date:3/4/2020)... ... March 04, 2020 , ... This month, Cognosante will make its annual ... will showcase both expanded and emerging offerings that align with the HIMSS annual theme, ... to be comprehensive, timely, and engaging. From Interoperability and HIE to ...
(Date:3/3/2020)... ... March 03, 2020 , ... Ideal Implant Incorporated Founder and ... technology at the IMCAS Innovation Shark Tank 2020 in Paris, France in January. ... and aesthetic science industries that promise to revolutionize medical practices in their fields. ...
Breaking Biology Technology:
(Date:3/2/2020)... ... , ... Philadelphia IP law firm Panitch Schwarze Belisario & Nadel LLP is ... a Partner, and Stephany G. Small, Ph.D., has joined the firm as a patent ... partner in the firm’s biotechnology and life science practice group. He has significant experience ...
(Date:2/28/2020)... ... February 27, 2020 , ... An upcoming episode of Advancements ... maladies, such as Inflammatory Bowel Disease (IBD), specifically Crohn’s Disease (Crohn’s), and Oncology. ... a novel platform developed by Deka Biosciences, Inc. (Deka Biosciences), that will enable ...
(Date:2/21/2020)... ... February 20, 2020 , ... ... today that it has entered into a collaboration with Takara Bio and HepaTx ... unique hepatocyte-like cells (iHeps) developed from adipose tissue-derived stromal cells (ASCs), and characterize ...
Breaking Biology News(10 mins):